The third edition of Flow Cytometry Guidelines provides the key aspects to consider when
performing flow cytometry experiments and includes comprehensive sections describing …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

These guidelines are a consensus work of a considerable number of members of the
immunology and flow cytometry community. They provide the theory and key practical …

The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we …

Multiple myeloma (MM) bears heterogeneous cells that poses a challenge for single-target
immunotherapies. Here we constructed bispecific CS1-BCMA CAR-T cells aiming to …

Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new
approaches to treatment are needed. T-cell therapies are a promising approach for treating …

All cases of multiple myeloma (MM) are preceded by precursor states termed monoclonal
gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). Genetic …

Background Major heterogeneity between laboratories in flow cytometry (FC) minimal
residual disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry …